Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE  >  Celltrion, Inc.    068270   KR7068270008

CELLTRION, INC.

(068270)
  Report  
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2019 1 165 B
EBIT 2019 449 B
Net income 2019 352 B
Finance 2019 198 B
Yield 2019 -
Sales 2020 1 418 B
EBIT 2020 596 B
Net income 2020 494 B
Finance 2020 571 B
Yield 2020 -
P/E ratio 2019 64,88
P/E ratio 2020 47,54
EV / Sales2019 19,8x
EV / Sales2020 16,0x
Capitalization 23 228 B
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
04/17CELLTRION : unveils P2 trial results for influenza antibody therapy
AQ
04/16CELLTRION : Diverging from US, Canada Approves Biosimilar Rituximab in Both Onco..
AQ
04/10CELLTRION : and iProgen Biotech announce partnership for development of novel AD..
AQ
04/07CELLTRION : Partners with the Canadian Biotech Company, iProgen Biotech to Devel..
BU
04/05CELLTRION : Completes Enrollment of Phase 3 Trial of CT-P17, Gives Update on Sub..
AQ
03/26CELLTRION : licenses out hypertrophic cardiomyopathy treatment to Japan
AQ
03/08CELLTRION : Healthcare wins biosimilar deals in Singapore and Thailand
AQ
01/31CROWDREVIEWS PARTNERED WITH IMAPAC P : 8th Annual Biologics Manufacturing Korea ..
AQ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/05SOUTH KOREA'S CELLTRION AIMS TO SET : chairman
RE
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 220 325  KRW
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Myung-Geun Oh Vice President & Operations Manager
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.19 604
IQVIA HOLDINGS INC17.40%26 900
LONZA GROUP24.03%23 473
INCYTE CORPORATION28.56%17 530
EXACT SCIENCES CORPORATION53.53%12 511
SEATTLE GENETICS, INC.22.03%11 153